**Palatin Technologies Inc. Reports Fiscal Year-End 2024 Results**
On October 1, 2024, Palatin Technologies Inc. (NYSE: PTN) hosted a conference call to discuss its fourth quarter and fiscal year-end 2024 operating results. Dr. Carl Spana, President and CEO, led the call alongside Stephen Wills, CFO, COO, Treasurer, and Secretary.
Dr. Spana welcomed participants and introduced the agenda, which included a financial update and review of corporate highlights. He then handed over to Wills to provide an overview of the company’s financial performance.
Wills began by discussing Palatin’s commercial product, Vyleesi, a bremelanotide injection developed to treat hypoactive sexual desire disorder (HSDD). He highlighted key corporate developments before delving into the financial results, which were influenced by various market and economic factors.
Throughout the call, participants were reminded that forward-looking statements made by Palatin are subject to risks and uncertainties, which may impact actual results. These statements are based on assumptions that may or may not prove accurate, and investors were encouraged to review the company’s SEC filings for a comprehensive understanding of these risks.
Leave a Reply